This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Patterson Companies (PDCO) Q1 Earnings & Sales Miss Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter 2023 results were adversely impacted by unfavorable currency movements.
Patterson Cos. (PDCO) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of -15.79% and 2.50%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Inks Deal to Acquire Midway Dental Supply
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Midway Dental Supply complements its efforts to offer products and services that deliver more effective, high-quality patient care.
Bruker (BRKR) Debuts Innovations for Proteomics & Metabolomics
by Zacks Equity Research
Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.
Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business
by Zacks Equity Research
According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.
Here's Why You Should Hold on to Nevro (NVRO) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.
Myriad Genetics (MYGN) Gets Extensive Coverage for BRACAnalysis
by Zacks Equity Research
Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.
What's in Store for Patterson Companies (PDCO) in Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at the Animal Health segment.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Here's Why Investors Should Retain Myriad Genetics (MYGN) Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics' (MYGN) better-than-expected results and strong testing volumes.
Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
5 Cheap Healthcare Stocks in 2022
by Tracey Ryniec
Energy, banks and agriculture have plenty of value stocks this year but what about healthcare?
Fresenius Medical (FMS) Robust Product Portfolio Drives Growth
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Analysts Estimate Patterson Cos. (PDCO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Patterson Cos. (PDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Abbott (ABT) to Offer New Treatment Option for Chronic Pain
by Zacks Equity Research
Abbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain.
Here's Why You Should Retain Exact Sciences (EXAS) Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences' (EXAS) better-than-expected results and robust Cologuard volumes.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.
Thermo Fisher (TMO) to Offer Wheat & Sesame Allergy Testing
by Zacks Equity Research
Thermo Fisher's (TMO) ImmunoCAP blood tests receive FDA approval for wheat and sesame allergy diagnosis.
PDCO vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?